JP2022536929A5 - - Google Patents

Info

Publication number
JP2022536929A5
JP2022536929A5 JP2021574188A JP2021574188A JP2022536929A5 JP 2022536929 A5 JP2022536929 A5 JP 2022536929A5 JP 2021574188 A JP2021574188 A JP 2021574188A JP 2021574188 A JP2021574188 A JP 2021574188A JP 2022536929 A5 JP2022536929 A5 JP 2022536929A5
Authority
JP
Japan
Prior art keywords
cancer
use according
transgene
adenovirus vector
oncolytic adenovirus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021574188A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022536929A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/FI2020/050422 external-priority patent/WO2020249873A1/en
Publication of JP2022536929A publication Critical patent/JP2022536929A/ja
Publication of JP2022536929A5 publication Critical patent/JP2022536929A5/ja
Priority to JP2025101398A priority Critical patent/JP2025138703A/ja
Pending legal-status Critical Current

Links

JP2021574188A 2019-06-14 2020-06-12 腫瘍溶解性アデノウイルスとチェックポイント阻害剤の併用療法 Pending JP2022536929A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025101398A JP2025138703A (ja) 2019-06-14 2025-06-17 腫瘍溶解性アデノウイルスとチェックポイント阻害剤の併用療法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962861339P 2019-06-14 2019-06-14
US62/861,339 2019-06-14
US202062988422P 2020-03-12 2020-03-12
US62/988,422 2020-03-12
PCT/FI2020/050422 WO2020249873A1 (en) 2019-06-14 2020-06-12 Oncolytic adenovirus and checkpoint inhibitor combination therapy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025101398A Division JP2025138703A (ja) 2019-06-14 2025-06-17 腫瘍溶解性アデノウイルスとチェックポイント阻害剤の併用療法

Publications (2)

Publication Number Publication Date
JP2022536929A JP2022536929A (ja) 2022-08-22
JP2022536929A5 true JP2022536929A5 (cg-RX-API-DMAC7.html) 2023-06-20

Family

ID=71670283

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021574188A Pending JP2022536929A (ja) 2019-06-14 2020-06-12 腫瘍溶解性アデノウイルスとチェックポイント阻害剤の併用療法
JP2025101398A Pending JP2025138703A (ja) 2019-06-14 2025-06-17 腫瘍溶解性アデノウイルスとチェックポイント阻害剤の併用療法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025101398A Pending JP2025138703A (ja) 2019-06-14 2025-06-17 腫瘍溶解性アデノウイルスとチェックポイント阻害剤の併用療法

Country Status (10)

Country Link
US (1) US20220251604A1 (cg-RX-API-DMAC7.html)
EP (1) EP3983004A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022536929A (cg-RX-API-DMAC7.html)
KR (1) KR20220024495A (cg-RX-API-DMAC7.html)
CN (1) CN113924117A (cg-RX-API-DMAC7.html)
AU (1) AU2020292610A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021025031A2 (cg-RX-API-DMAC7.html)
CA (1) CA3138834A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202111820PA (cg-RX-API-DMAC7.html)
WO (1) WO2020249873A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022170919A1 (zh) * 2021-02-09 2022-08-18 南京惟亚德生物医药有限公司 一种重组溶瘤腺病毒及其应用
CA3233797A1 (en) 2021-10-04 2023-04-13 Tatiana KUDLING An oncolytic virus vector coding for interleukin-7 (il-7) polypeptide
KR20250158053A (ko) * 2023-03-01 2025-11-05 틸트 바이오세러퓨틱스 오이 종양용해성 아데노바이러스 벡터의 새로운 투여 요법
CN121335710A (zh) * 2023-04-07 2026-01-13 上海复诺健生物科技有限公司 重组溶瘤病毒与检查点抑制剂的组合用于治疗癌症
CN120835927A (zh) * 2023-09-28 2025-10-24 复旦大学附属华山医院 用于治疗胶质瘤的组合物
CN117205304A (zh) * 2023-10-18 2023-12-12 中国人民解放军海军军医大学第三附属医院 维生素c和il-2在制备免疫检查点抑制剂增敏药物中的应用
WO2025159067A1 (ja) * 2024-01-22 2025-07-31 国立大学法人 鹿児島大学 腫瘍溶解性ウイルス及びそれを用いたがん治療

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
EP3461491B1 (en) * 2013-04-18 2024-11-13 TILT Biotherapeutics Oy Enhanced adoptive cell therapy

Similar Documents

Publication Publication Date Title
O'Bryan et al. Oncolytic virotherapy for breast cancer treatment
US11155622B2 (en) Virus encoding an anti-TCR-complex antibody or fragment
Howells et al. Oncolytic viruses—interaction of virus and tumor cells in the battle to eliminate cancer
JP2025100670A5 (cg-RX-API-DMAC7.html)
CN105307671B (zh) 增强过继细胞疗法
Dong et al. Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages
JP2020521471A (ja) 導入遺伝子を保持する組換えアデノウイルス
US11690913B2 (en) Combining adenovirus and checkpoint inhibitors for treating cancer
JP2021533789A5 (cg-RX-API-DMAC7.html)
JP2018509914A (ja) 二重特異性抗体をコードする腫瘍溶解性アデノウイルスおよびそれに関連する方法と使用
JP2020504767A (ja) 武装した複製可能な腫瘍溶解性アデノウイルス
Huang et al. Bispecific T cell engagers and their synergistic tumor immunotherapy with oncolytic viruses
JP2024510712A (ja) Il-15をコードするアデノウイルス
WO2013123861A1 (zh) 一种能与egfr、her2、vegf高效结合的融合蛋白、其编码序列及用途
Corti et al. Novel immune targets for the treatment of triple-negative breast cancer
Sultan et al. Precision oncolytic viral therapy in colorectal cancer: Genetic targeting and immune modulation for personalized treatment
Li et al. Oncolytic viruses in cancer immunotherapy
SK282235B6 (sk) Lieková kombinácia na transfekciu a expresiu exogénov in vivo alebo ex vivo
JP7381604B2 (ja) 癌を治療するための多価pd-l1結合化合物
Zhu et al. Research progress on HER2-specific chimeric antigen receptor T cells for immunotherapy of solid tumors
Mirbahari et al. Oncolytic Viruses Reshape PD‐1/PD‐L1 Signaling: Mechanisms and Clinical Synergy With Immune Checkpoint Blockade
JP2022502066A (ja) 癌治療のための修飾b5r遺伝子を有する腫瘍溶解性ワクシニアウイルス
Wang et al. Novel combination oncolytic adenoviral gene therapy armed with Dm-dNK and CD40L for breast cancer
CA3149918A1 (en) Pharmaceutical composition for treating cancer comprising anticancer virus, immune checkpoint inhibitor and hydroxyurea as active ingredients
JP7699122B2 (ja) 複製促進腫瘍溶解性アデノウイルス